Seven in ten autoimmune disease patients in India are women, say experts at IRACON 2025
… Rheumatology Association (IRACON 2025), held at Yashobhoomi in Dwarka. The conference, India’s largest gathering on rheumatology, brought together …
… Rheumatology Association (IRACON 2025), held at Yashobhoomi in Dwarka. The conference, India’s largest gathering on rheumatology, brought together …
Single center study of pregnancy outcomes in 189 women (131 RA, 29 SpA, 29 PsA). Stats for RA/SpA/PsA — Live
… rheumatology assessment and temporal artery ultrasound demonstrated increased intima-media thickness in the superficial temporal, frontal, and …
The patient has a rash on her cheeks and nose with sparing of the nasolabial folds, in addition to involvement
Sensitising family doctors. The problem of the diagnostic delay is linked to the lack of rheumatology specialists on the territory,
Adults with psoriatic arthritis saw early improvements in their symptoms and key health-related quality-of-life measures with guselkumab treatment that were
… Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29, 2025. “We are honored to be selected by
Prof. (Dr.) Pradipta Sekhar Patro, Head of Department of Clinical Immunology and Rheumatology at the Institute of Medical Sciences and
Pregnancies with psoriatic arthritis are associated with increased odds of preterm births, with disease load before pregnancy and treatment strategy
Nature Reviews Rheumatology, Published online: 13 October 2025; doi:10.1038/s41584-025-01310-0 Generative artificial intelligence promises to reshape clinical care in rheumatology by
A widely prescribed opioid provides only minimal relief for chronic pain and carries significant risk for serious side effects, highlighting
Ultrasonography-guided synovial biopsy reveals distinct features of noninflammatory and persistent inflammatory phenotypes in refractory rheumatoid arthritis, supporting subtype-guided care. Medscape
… rheumatic drug — across six rheumatology centers in Germany, Portugal and Serbia. All participants underwent functional MRI at baseline
Managing Hereditary Angioedema with Normal C1 Inhibitor. 13 Oct 2025. Rheumatology · View All News. Woman holding pill pack …
In tofacitinib-treated patients with RA and a history of atherosclerotic CVD, occurrence of MACE is lower with statin use; tofacitinib
Expert Rev Clin Immunol. 2025 Oct 13. doi: 10.1080/1744666X.2025.2575355. Online ahead of print. ABSTRACT INTRODUCTION: Difficult-to-treat psoriatic arthritis (D2T-PsA) is
Expert Rev Clin Immunol. 2025 Oct 13. doi: 10.1080/1744666X.2025.2575448. Online ahead of print. ABSTRACT INTRODUCTION: Immunoglobulin G4 (IgG4)-related disease (IgG4-RD)
JAMA Intern Med. 2025 Oct 13. doi: 10.1001/jamainternmed.2025.5201. Online ahead of print. NO ABSTRACT PMID:41082225 | DOI:10.1001/jamainternmed.2025.5201
Asian Pac J Allergy Immunol. 2025 Oct 13. doi: 10.12932/AP-090625-2090. Online ahead of print. ABSTRACT BACKGROUND: Asthma is a heterogeneous
Eur Geriatr Med. 2025 Oct 13. doi: 10.1007/s41999-025-01327-4. Online ahead of print. ABSTRACT AIM: To examine the association of muscle
Drugs Real World Outcomes. 2025 Oct 13. doi: 10.1007/s40801-025-00514-w. Online ahead of print. ABSTRACT BACKGROUND: Older adults are under-represented in
Clin Rheumatol. 2025 Oct 13. doi: 10.1007/s10067-025-07747-8. Online ahead of print. NO ABSTRACT PMID:41082107 | DOI:10.1007/s10067-025-07747-8
Rheumatol Int. 2025 Oct 13;45(11):248. doi: 10.1007/s00296-025-05965-6. NO ABSTRACT PMID:41081910 | DOI:10.1007/s00296-025-05965-6
Rheumatol Int. 2025 Oct 13;45(11):249. doi: 10.1007/s00296-025-05997-y. ABSTRACT To examine the central sensitization and its determinants in systemic lupus erythematosus
Osteoporos Int. 2025 Oct 13. doi: 10.1007/s00198-025-07722-8. Online ahead of print. ABSTRACT The impact of romosozumab on the bone mineral
Osteoporos Int. 2025 Oct 13. doi: 10.1007/s00198-025-07706-8. Online ahead of print. ABSTRACT This first-of-its-kind survey reveals deep gaps in awareness,
J Allergy Clin Immunol. 2025 Jul 16:S0091-6749(25)00623-2. doi: 10.1016/j.jaci.2025.05.028. Online ahead of print. ABSTRACT BACKGROUND: Omalizumab, a therapeutic mAb targeting